Abstract
Patients with established coronary artery disease remain at elevated risk of major adverse cardiac events. The goal of this study was to evaluate the utility of plasminogen activator inhibitor-1-positive platelet-derived extracellular vesicles as a biomarker for major adverse cardiac events and to explore potential underlying mechanisms. Our study suggests these extracellular vesicles as a potential biomarker to identify and a therapeutic target to ameliorate neointimal formation of high-risk patients.
Original language | English (US) |
---|---|
Pages (from-to) | 985-997 |
Number of pages | 13 |
Journal | JACC: Basic to Translational Science |
Volume | 7 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2022 |
Externally published | Yes |